Insight & Intelligence

More »

July 1, Vol. 28, No. 13

  • Feature Articles

    • Primer on Regulation of Diagnostic Assays
    • Jeffrey N. Gibbs
    • Historically, pharmaceutical and diagnostic companies in the US have inhabited parallel regulatory universes Although both sets of firms are overseen by the FDA and are subject to some identical provisions, they have been regulated independently For the pharma industry, regulatory ... more »
    • Conquering RNAi Delivery Challenges
    • Kathy Liszewski
    • RNA interference (RNAi) is making great strides as an indispensable strategy for target-specific knockdown of gene expression Emerging second-generation technologies represent advances in RNAi design, efficiency, and efficacy Yet, daunting obstacles remain, such as how to deliver RNAi compounds to ... more »
    • Sample Prep Initiatives Will Advance Proteomics
    • Nina Flanagan
    • Proteomics continues to have an increasing role in drug discovery and diagnostics development and also provides a better understanding of disease Advances in technology are providing innovative methods to enhance protein analysis with an increased focus on sample preparation Cambridge ... more »
    • Compound Discovery Tools Still Evolving
    • Elizabeth Lipp
    • In a perfect high-throughput screening world, hit-to-lead discovery scientists would have many chemical series from which to choose Unfortunately, as Tara Stauffer, research scientist at Pharmacopeia (wwwpharmacopeiacom), noted, “determining the optimal series for further chemical development can be a daunting ... more »
    • Biomagnetic Separations See Increased Use
    • Gail Dutton
    • Biomagnetic separations are expanding into nontraditional fields including neurology and proteomics as new disciplines discover the availability of gentle ways to separate cells and even classes of cells It seems that many people who have never used magnetic separation are ... more »
    • Reducing Downstream Purification Costs
    • Angelo DePalma
    • Over the years, bioprocessors could, at various times, debate whether upstream or downstream operations represented the slow step, relatively speaking, of therapeutic protein production Now, with protein titers rising inexorably, purification is likely to remain rate-limiting, for a given facility ... more »
    • Staying Ahead of Upstream Developments
    • Susan Aldridge, Ph.D.
    • The whole value chain, from cell culture and upstream processing to formulation and drug delivery, was the focus of Informa’s “BioProcess International” conference held recently in Vienna A major theme of the meeting was how developments in upstream processing such ... more »
    • Trends in Synthesis and Manufacturing
    • Diana Gitig, Ph.D.
    • Peptides are popular, and these days researchers want more and more from them They want increasingly complex peptides, they want high-quality peptides that conform to cGMP, and they want larger and larger quantities of pure peptides And they want them ... more »

Be sure to take the GEN Poll

{{ vm.poll.Title }}

More »